A comparison of overall survival with 40 and 50 mg/m 2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data
2016 ◽
Vol 143
(2)
◽
pp. 246-251
◽
2003 ◽
Vol 1
(5)
◽
pp. S51
◽
Keyword(s):
2020 ◽
Keyword(s):
2021 ◽
Vol 21
◽
pp. S444-S445
Keyword(s):
2020 ◽
Vol 20
(10)
◽
pp. 704-711